How much will Olaparib be reimbursed after it is included in medical insurance?

Olaparib has been approved by the State Food and Drug Administration in 2018 to enter the domestic market and is sold under the trade name Lipuzhuo. After being launched in the country, it has passed the relevant policies of the National Medical Insurance Administration and entered the scope of Class B medical insurance, but it is limited to patients who meet the indications. Patients who do not meet the conditions can only purchase it at their own expense. Olaparib’s reimbursement conditions include adult patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and metastatic castration-resistant prostate cancer. Specification The price of 150mg*56 tablets per box may be around 6,000 yuan. The reimbursement ratio is different in different regions, and the price after reimbursement may be different.